The new industrial sector capital is making moves; Nanjing Pharmaceutical is aiming to build a biotech and medical ecosystem.

View Original
MarsBitNews
Nanjing Pharmaceutical: Plans to invest no more than 450 million yuan to establish a dedicated acquisition fund to acquire equity in Daqing Biological and Kejian Technology
Mars Finance News, May 21 — Nanjing Pharmaceutical announced that the company plans to invest no more than 450 million yuan, jointly investing with New Industrial Investment and New Industrial Medical M&A Fund to establish the DaQing M&A Fund.
After the fund's establishment, it will be specifically used to acquire a 44.95% stake in DaQing Biotech and a 50.98% stake in Kejian Technology, with a total acquisition amount of 747 million yuan.
After the transaction is completed, DaQing M&A Fund, DaQing Biotech, and Kejian Technology will be included in the company's consolidated financial statements. (Company Announcement)
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned